Robert L. Coleman, MD, FACOG, FACS, Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the results of phase III VELIA trial in patients with advanced ovarian cancer.
Data from the phase III trial presented at the 2019 ESMO Congress demonstrated that the frontline combination of veliparib and chemotherapy followed by veliparib maintenance led to a significant improvement in progression-free survival (PFS) versus chemotherapy and placebo followed by placebo maintenance among patients. with newly diagnosed, metastatic ovarian cancer.
The regimen was evaluated among the general population, patients with germline and somatic BRCA mutations, and those with homologous recombination deficiency (HRD), says Coleman. Among patients with BRCA mutations, the median PFS was 34.7 months versus 22 months in the control arm (HR, 0.44). Furthermore, PFS was 31.9 months in the veliparib arm versus 20.5 months in the control arm among patients with HRD (HR, 0.57). Across the overall population, the PFS was 23.5 months versus 17.3 months with veliparib versus control arm (HR, 0.68). Notably, patients were randomized to treatment at the start of chemotherapy rather than following a response to platinum-based chemotherapy, says Coleman.
For more resources and information from the 2019 ESMO Congress: http: //targetedonc.com/conference/esm …